MedeliX
Start asking

eptifibatide

Eptifibatide Accord · ATC code B01AC16

Also known as: Eptifibatid

Key facts
Active substance
eptifibatide
Drug class
Antithrombotic
ATC code
B01AC16
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Eptifibatide Accord 0.75 mg/ml solution for infusion · Eptifibatide Accord 2 mg/ml solution for injection
Information as of
2026-10-29

Key facts

Eptifibatide is an intravenous glycoprotein IIb/IIIa inhibitor that inhibits platelet aggregation. It is used in hospital together with acetylsalicylic acid and unfractionated heparin in acute coronary syndromes.

What it is used for

  • Prevention of early myocardial infarction in adults with unstable angina or non-Q-wave myocardial infarction, last chest pain within 24 hours, with ECG changes and/or elevated cardiac enzymes.
  • For use with acetylsalicylic acid and unfractionated heparin.

Dosing

  • Eptifibatide Accord solution for injection (bolus) and solution for infusion are used together: intravenous bolus of 180 microgram/kg as soon as possible after diagnosis, followed by a continuous infusion of 2 microgram/kg/min.
  • Infusion for up to 72 hours, until CABG surgery or until discharge; if PCI is performed, continue for 20-24 hours post-PCI, overall maximum 96 hours.
  • Moderate renal impairment (creatinine clearance ≥ 30 - < 50 ml/min): bolus 180 microgram/kg, then infusion of 1.0 microgram/kg/min. More severe renal impairment: contraindicated.
  • Terminate the infusion immediately if emergency cardiac surgery is needed. Hospital use only, by specialist physicians.

Contraindications

  • Hypersensitivity; gastrointestinal, gross genitourinary or other active abnormal bleeding within the previous 30 days; bleeding diathesis.
  • Stroke within 30 days or any history of haemorrhagic stroke; intracranial disease (neoplasm, arteriovenous malformation, aneurysm); major surgery or severe trauma within past 6 weeks.
  • Thrombocytopenia (< 100,000 cells/mm3); prothrombin time > 1.2 times control or INR ≥ 2.0; severe hypertension (systolic > 200 mm Hg or diastolic > 110 mm Hg on treatment).
  • Severe renal impairment (creatinine clearance < 30 ml/min) or dialysis; clinically significant hepatic impairment; concomitant another parenteral GP IIb/IIIa inhibitor.

Important warnings

  • Bleeding: observe patients carefully, especially at arterial access sites; higher risk in women, the elderly, low body weight and moderate renal impairment.
  • Immune-mediated thrombocytopenia may occur: monitor platelets before treatment, within 6 hours, and at least daily thereafter.
  • Before starting, check PT, aPTT, serum creatinine, platelet count, haemoglobin and haematocrit.
  • Contains sodium.

Side effects

  • Very common: bleeding (major and minor, e.g. femoral artery access, gastrointestinal, genitourinary, retroperitoneal, intracranial).
  • Common: cardiac arrest, ventricular fibrillation, ventricular tachycardia, congestive heart failure, atrioventricular block, atrial fibrillation, shock, hypotension, phlebitis (largely related to the underlying disease).
  • Uncommon: thrombocytopenia, cerebral ischaemia.

Interactions

  • Warfarin and dipyridamole did not appear to increase the bleeding risk.
  • Thrombolytics: limited data; bleeding risk appeared increased with streptokinase – see the full text.

Pregnancy and breastfeeding

  • Should not be used during pregnancy unless clearly necessary.
  • Interruption of breast-feeding during treatment is recommended.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Source: European Medicines Agency (EMA), product information

Germany

  • EptifibatidAltamedics Gmbh · 2 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • EpticardVEM İLAÇ SAN. VE TİC. A.Ş. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 12 more European countries
Bulgaria
Ептифибатид Ромфарм
Denmark
Eptifibatide "ctruz"
Finland
Eptifibatide Ctruz
Hungary
Eptifibatide Rompharm
Iceland
Eptifibatide Accord
Ireland
Eptifibatide Jed
Italy
Eptifibatide Alida
Liechtenstein
Eptifibatide Accord
Netherlands
Eptifibatide Aftpharm
Norway
Eptifibatide Accord, Eptifibatide Ctruz
Romania
Eptifibatidă Rompharm
Sweden
Eptifibatide Ctruz

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Eptifibatide Accord – EPAR, Product Information. 2026-10-29. https://www.ema.europa.eu/en/documents/product-information/eptifibatide-accord-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  4. Wikidata (CC0): ATC B01AC.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.